Home/Filings/4/0000899243-19-025695
4//SEC Filing

SVF Endurance (Cayman) Ltd 4

Accession 0000899243-19-025695

CIK 0001706431other

Filed

Oct 16, 8:00 PM ET

Accepted

Oct 17, 4:55 PM ET

Size

16.4 KB

Accession

0000899243-19-025695

Insider Transaction Report

Form 4
Period: 2019-10-16
Transactions
  • Conversion

    Series B Convertible Preferred Stock

    2019-10-166,111,1110 total(indirect: See footnote)
    Common Stock (6,111,111 underlying)
  • Conversion

    Common Stock, par value $0.0001 per share

    2019-10-16+21,666,66621,666,666 total(indirect: See footnote)
  • Purchase

    Common Stock, par value $0.0001 per share

    2019-10-16$20.00/sh+950,000$19,000,00022,616,666 total(indirect: See footnote)
  • Conversion

    Series A-1 Convertible Preferred Stock

    2019-10-1615,555,5550 total(indirect: See footnote)
    Common Stock (15,555,555 underlying)
Transactions
  • Purchase

    Common Stock, par value $0.0001 per share

    2019-10-16$20.00/sh+950,000$19,000,00022,616,666 total(indirect: See footnote)
  • Conversion

    Series B Convertible Preferred Stock

    2019-10-166,111,1110 total(indirect: See footnote)
    Common Stock (6,111,111 underlying)
  • Conversion

    Common Stock, par value $0.0001 per share

    2019-10-16+21,666,66621,666,666 total(indirect: See footnote)
  • Conversion

    Series A-1 Convertible Preferred Stock

    2019-10-1615,555,5550 total(indirect: See footnote)
    Common Stock (15,555,555 underlying)
Transactions
  • Conversion

    Common Stock, par value $0.0001 per share

    2019-10-16+21,666,66621,666,666 total(indirect: See footnote)
  • Conversion

    Series B Convertible Preferred Stock

    2019-10-166,111,1110 total(indirect: See footnote)
    Common Stock (6,111,111 underlying)
  • Purchase

    Common Stock, par value $0.0001 per share

    2019-10-16$20.00/sh+950,000$19,000,00022,616,666 total(indirect: See footnote)
  • Conversion

    Series A-1 Convertible Preferred Stock

    2019-10-1615,555,5550 total(indirect: See footnote)
    Common Stock (15,555,555 underlying)
Footnotes (3)
  • [F1]The Series A-1 Convertible Preferred Stock and the Series B Convertible Preferred Stock each converted into Vir Biotechnology, Inc. common stock on a one-to-one basis and had no expiration date.
  • [F2]Represents securities held directly by SVF Endurance (Cayman) Limited. SVF Endurance (Cayman) Limited is a wholly-owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
  • [F3](continued from footnote 2) SBIA UK is wholly owned by SoftBank Group Corp. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose.

Issuer

Vir Biotechnology, Inc.

CIK 0001706431

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001782338

Filing Metadata

Form type
4
Filed
Oct 16, 8:00 PM ET
Accepted
Oct 17, 4:55 PM ET
Size
16.4 KB